Newton’s Neurolens® N3 Receives CE Mark Under EU MDR

DALLAS, Nov. 17, 2026 /PRNewswire/ -- Newton, Inc., the eye care technology company behind Neurolens®, today announced that the Neurolens N3 has received CE marking under the European Union Medical Device Regulation (EU MDR). The certification, issued by Intertek Medical Notified Body AB, clears the N3 for commercialization across the European Union and European Economic Area.

The EU MDR sets some of the most demanding requirements for medical devices anywhere in the world, with heightened standards for clinical evidence, quality management, technical documentation and post-market surveillance. Earning certification under the regulation marks a major step in Newton’s international growth, and comes at a time of critical unmet need: A survey of more than 8,000 adults across nine European countries found that nearly four in five had experienced a headache in the past year, with researchers concluding that headache disorders have “very high personal impact” in the EU.1 Davis Corley, CEO of Newton, stated “CE marking under the MDR is a defining milestone for Newton. It reflects the rigor behind our technology and our team, and it opens the door for eye care professionals across Europe to offer their patients a new answer to symptoms they’ve often lived with for years.”

Sign up for Blog Updates